Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$144.95 - $152.29 $4.35 Million - $4.57 Million
-30,030 Reduced 90.44%
3,174 $480,000
Q2 2022

Aug 03, 2022

BUY
$83.14 - $145.99 $278,934 - $489,796
3,355 Added 11.24%
33,204 $4.84 Million
Q1 2022

May 04, 2022

BUY
$110.08 - $142.92 $363,814 - $472,350
3,305 Added 12.45%
29,849 $3.54 Million
Q4 2021

Feb 04, 2022

BUY
$99.73 - $148.48 $2.19 Million - $3.26 Million
21,925 Added 474.67%
26,544 $3.66 Million
Q3 2021

Oct 07, 2021

BUY
$98.85 - $138.91 $84,615 - $118,906
856 Added 22.75%
4,619 $642,000
Q2 2021

Aug 04, 2021

BUY
$65.78 - $105.02 $19,339 - $30,875
294 Added 8.48%
3,763 $365,000
Q1 2021

May 04, 2021

BUY
$64.07 - $91.75 $49,718 - $71,198
776 Added 28.82%
3,469 $237,000
Q4 2020

Feb 02, 2021

BUY
$65.07 - $98.24 $175,233 - $264,560
2,693 New
2,693 $231,000
Q3 2020

Oct 09, 2020

SELL
$59.04 - $77.95 $208,706 - $275,553
-3,535 Closed
0 $0
Q2 2020

Jul 08, 2020

BUY
$29.01 - $74.23 $102,550 - $262,403
3,535 New
3,535 $258,000
Q2 2019

Aug 02, 2019

SELL
$39.79 - $67.01 $154,265 - $259,797
-3,877 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$34.52 - $53.29 $133,834 - $206,605
3,877 New
3,877 $200,000
Q3 2018

Nov 14, 2018

SELL
$32.79 - $43.0 $40,200 - $52,718
-1,226 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$23.62 - $42.29 $3,306 - $5,920
140 Added 12.89%
1,226 $48,000
Q1 2018

May 09, 2018

BUY
$22.49 - $34.56 $12,414 - $19,077
552 Added 103.37%
1,086 $28,000
Q4 2017

Feb 20, 2018

SELL
$20.44 - $35.56 $11,425 - $19,878
-559 Reduced 51.14%
534 $14,000
Q3 2017

Nov 13, 2017

BUY
$23.54 - $38.21 $2,448 - $3,973
104 Added 10.52%
1,093 $41,000
Q2 2017

Aug 14, 2017

BUY
N/A
989
989 $25,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.